said that if it comes down to a question of funding vaccine candidates in a clinical phase the issue of effectiveness will have to considered
Having said that, if it comes down to a question of funding vaccine candidates in a clinical phase, the issue of effectiveness will have to be considered.
said that, if it comes down to a question of funding vaccine candidates in a clinical phase, the issue of effectiveness will have to considered.